J
John R. Graybill
Researcher at United States Department of Veterans Affairs
Publications - 13
Citations - 856
John R. Graybill is an academic researcher from United States Department of Veterans Affairs. The author has contributed to research in topics: Amphotericin B & Mycosis. The author has an hindex of 11, co-authored 13 publications receiving 831 citations. Previous affiliations of John R. Graybill include Santa Clara Valley Medical Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Fluconazole Therapy for Coccidioidal Meningitis
John N. Galgiani,Antonino Catanzaro,Gretchen A. Cloud,Jean Higgs,Barry A. Friedman,Robert A. Larsen,John R. Graybill +6 more
TL;DR: A collaborative study of the treatment of coccidioidal meningitis with fluconazole corroborate those of earlier investigations and offer guidance for future studies.
Journal ArticleDOI
Itraconazole treatment of coccidioidomycosis
TL;DR: Itraconazole appears efficacious and very well tolerated in patients with coccidioidomycosis.
Journal ArticleDOI
Pharmacology and toxicity of high-dose ketoconazole.
A M Sugar,S G Alsip,John N. Galgiani,John R. Graybill,W E Dismukes,G A Cloud,P C Craven,David A. Stevens +7 more
TL;DR: Neither concentration in serum, toxicity, nor outcome correlated with dose, calculated in milligrams per kilogram at the fixed doses (400-mg increments) under study, suggesting that individual drug disposition was not an important factor in outcome or toxicity.
Journal ArticleDOI
Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression
John R. Graybill,John R. Graybill,Rosie Bocanegra,Laura K. Najvar,David Loebenberg,Mike F. Luther +5 more
TL;DR: Outbred ICR mice were immune suppressed either with hydrocortisone or with 5-fluorouracil and were infected intranasally with Aspergillus fumigatus and benefited from either G-CSF or triazoles, and the effect of the combination was additive rather than antagonistic.
Journal ArticleDOI
Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
Hail M. Al-Abdely,Hail M. Al-Abdely,John R. Graybill,John R. Graybill,David Loebenberg,Peter C. Melby,Peter C. Melby +6 more
TL;DR: Very good activity of SCH 56592 is indicated against cutaneous leishmaniasis due to L. amazonensis infection and, to a lesser degree, against visceral leish maniasis dueto L. donovani infection in susceptible BALB/c mice.